Mylan (NASDAQ: MYL) reported disappointing 2018 fourth-quarter earnings results in February. The drugmaker continued to struggle in the U.S. market especially. However, Mylan provided full-year 2019 guidance that pointed to better days ahead.
Do Not Allow Advertisers to Use My Personal information
Copyright © 2023,